Clinuvel Pharmaceuticals Ltd CLVLY:OTCPK

RT Quote | Exchange | USD
Last | 3:58 PM EDT
10.53quote price arrow down-1.04 (-8.99%)
Volume
65,552
52 week range
9.94 - 31.44
Loading...
  • Open11.12
  • Day High11.18
  • Day Low10.53
  • Prev Close11.57
  • 52 Week High31.44
  • 52 Week High Date09/23/21
  • 52 Week Low9.94
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap575.14M
  • Shares Out49.41M
  • 10 Day Average Volume5,609
  • Dividend0.02
  • Dividend Yield0.17%
  • Beta0.99
  • YTD % Change-47.11

KEY STATS

  • Open11.12
  • Day High11.18
  • Day Low10.53
  • Prev Close11.57
  • 52 Week High31.44
  • 52 Week High Date09/23/21
  • 52 Week Low9.94
  • 52 Week Low Date05/12/22
  • Market Cap575.14M
  • Shares Out49.41M
  • 10 Day Average Volume5,609
  • Dividend0.02
  • Dividend Yield0.17%
  • Beta0.99
  • YTD % Change-47.11

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date09/03/2021
  • Div Amount0.0182
  • Split Date-
  • Split Factor-

Latest On Clinuvel Pharmaceuticals Ltd

There is no recent news for this security.

Profile

MORE
Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. Its principal activity consists of commercializing and distribution in Europe and the United States, Israel, and Australia of its drug candidate SCENESSE for the prevention of phototoxicity (anaphylactoid reactions and...
Willem Blijdorp
Non-Executive Independent Chairman of the Board
Philippe Wolgen M.D.
Chief Executive Officer, Managing Director, Executive Director
Darren Keamy CPA
Chief Financial Officer, Company Secretary
Address
L 11 535 Bourke St
Melbourne, VIC
3000
Australia